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Abstract
FDA drug labels are rich sources of informa-
tion about drugs and drug–disease relations,
but their complexity makes them challenging
texts to analyze in isolation. To overcome this,
we situate these labels in two health knowl-
edge graphs: one built from precise structured
information about drugs and diseases, and an-
other built entirely from a database of clinical
narrative texts using simple heuristic methods.
We show that Probabilistic Soft Logic models
defined over these graphs are superior to text-
only and relation-only variants, and that the
clinical narratives graph delivers exceptional
results with little manual effort. Finally, we
release a new dataset of drug labels with anno-
tations for five distinct drug–disease relations.
1 Introduction
The FDA Online Label Repository is a pub-
licly available database of texts that provide de-
tailed information about pharmaceutical drugs, in-
cluding active ingredients, approved usage, warn-
ings, and contraindications. Although the labels
have predictable subsections and use highly regu-
lated language, they are nuanced and presuppose
deep medical knowledge, since they are intended
for use by healthcare professionals (Shrank and
Avorn, 2007). This makes them a formidable chal-
lenge for information extraction systems.
At the same time, existing medical ontologies
contain diverse structured information about drugs
and diseases. The drug labels can be situated in a
larger health knowledge graph that brings together
these sources of information, which can then be
used to understand the labels. Figure 1 illus-
trates the guiding intuition; if our goal is to deter-
mine whether to add the dashed TREATS edge, we
should take advantage of the label for Medrol as
well as the drug–drug, drug–disease, and disease–
disease relations that are observed. Hristovski
Figure 1: Illustrative knowledge graph for the pre-
diction of the relation between a drug (Medrol) and
a disease (dermatitis). In favor of a TREATS rela-
tion: Medrol has the same pharmacologic class as Bay-
cadron, which treats dermatitis; dermatitis has the same
morphology as neuritis, which is treated by Medrol.
Against a TREATS relation: dermatitis has the same
site as hypersensitivity, which is not treated by Medrol.
Our Probabilistic Soft Logic approach learns to com-
bine these factors.
et al. (2006) describe a similar intuition with what
they call “discovery patterns”.
In this paper, we show that Probabilistic Soft
Logic (PSL; Bro¨cheler et al. 2010; Bach et al.
2013) is an effective tool for modeling drug la-
bels situated in larger health knowledge graphs.
A PSL model is a set of logical statements inter-
preted as defeasible relational constraints, and the
relative weights of these constraints are learned
from data. In PSL, we can directly state intu-
itions like ‘if some drugs share a substance, then
they might treat the same diseases’ and ‘if two dis-
eases share a classification, they might be treated
by the same drugs’. Fakhraei et al. (2013) show
the value of these ideas for drug–disease relation-
ships. We extend their basic idea by adapting the
method of West et al. (2014): our PSL models
combine graph-based constraints with constraints
derived from a separate sequence-labeling model
applied to the drug label texts.
The most expensive parts of this model are the
structured ontologies used to build the graph. Each
ontology is a large, highly specialized project re-
quiring extensive human expertise. This motivates
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us to seek out alternatives. To this end, we also
evaluate on a graph that is derived entirely from
clinical texts. Using only key-phrase matching, we
instantiate a large, noisy graph with the same core
structure as in figure 1, and we show that the PSL
model is robust to such noisy inputs. By combin-
ing this graph with our structured one, we achieve
larger gains, but the clinical narratives graph is ef-
fective on its own, and thus emerges as a viable
option for domains lacking pre-built ontologies.
Our evaluations are centered around a new
dataset of annotated drug labels. In this dataset,
spans of text identifying diseases are annotated
with labels summarizing the drug–disease rela-
tionship expressed in the label.1 We show that our
full PSL model yields superior predictions on this
dataset, as compared with ablations using only the
texts and only the graph edges derived from struc-
tured and textual sources.
2 Medical Ontologies Knowledge Graph
Our health knowledge graphs are focused on drugs
and diseases related to obesity. We first introduce
the graph we built from structured sources (802
nodes, 883 edges).
2.1 FDA Online Label Repository
From the FDA Online Label Repository2 we ex-
tracted the drug labels matching at least one of
the following keywords: “obesity”, “overweight”,
“asthma”, “coronary heart disease”, “hypercholes-
terolemia”, “gallstones”, “gastroesophageal re-
flux”, “gout”, “hypertriglyceridemia”, “sleep ap-
nea”, “peripheral vascular disease”, “chronic ve-
nous insufficiencies”. This is the set of diseases in
the i2b2 Obesity Challenge (Uzuner, 2009), with
some omissions for the sake of precision.
The FDA individuates drugs in a very fine-
grained way, resulting in many duplicate or near-
duplicate labels (there are usually multiple brands
and versions of a drug). To ensure no duplicates
in the intuitive sense, we hand-filtered to a set of
106 drug labels. These labels mention 198 distinct
diseases, resulting in 1,110 drug–disease pairs.
2.2 Drug–Disease Annotations
Disease mentions in drug labels have a variety of
senses. Guided by our own analysis of the rele-
1https://github.com/roamanalytics/
roamresearch/tree/master/Papers/
PSL-drugs-diseases
2https://labels.fda.gov
Relations Agreement
PREVENTS 154 63.0
TREATS 4,425 67.3
TREATS OUTCOMES 2,268 67.1
NOT ESTABLISHED 241 35.1
NOT RECOMMENDED 262 49.5
OTHER 1,262 35.9
Table 1: Drug–disease relations collected using crowd-
sourcing. The “Agreement” column gives the aver-
age agreement between workers and the labels inferred.
Higher agreement correlates strongly with the degree to
which the information is explicit in the label text.
vant sentences, we settled on the following set of
relational descriptions, with input from clinical ex-
perts acting as consultants to us:
• The drug prevents the disease (our label is
PREVENTS).
• The drug treats the disease (TREATS).
• The drug treats outcomes of the disease
(TREATS OUTCOMES).
• The safety/effectiveness of the drug has not
been established for the disease (NOT ES-
TABLISHED).
• The drug is not recommended for the disease
(NOT RECOMMENDED).
We emphasize the clinical importance of distin-
guishing between treating a disease and treating its
outcomes. Cancer, for example, is not treated with
Depo-Medrol, but hypercalcemia associated with
cancer is. Similarly, NOT RECOMMENDED iden-
tifies a contraindication, a specific kind of guid-
ance, whereas the superficially similar NOT ES-
TABLISHED has a more open meaning: the rela-
tion could be TREATS, but this has not been tested
or a clinical trial failed to demonstrate its efficacy.
We crowdsourced the task of assigning these la-
bels to disease mention spans. Workers saw the
entire label text, with our target diseases high-
lighted, and were asked to select the best state-
ment among those provided above. We launched
our task on Figure Eight, asking for 5 judg-
ments for each drug–disease pair. To infer a la-
bel for each example from these responses, we ap-
plied Expectation Maximization (EM), which es-
timates the reliability of each worker and weights
their contributions accordingly (Dawid and Skene,
1979). Table 1 reports average agreement between
workers and the inferred label. The PREVENTS,
TREATS, and TREATS OUTCOMES relations are
usually stated directly in drug labels, leading to
high agreement. In contrast, NOT ESTABLISHED,
NOT RECOMMENDED, and OTHER are more sub-
tle and diverse, leading to lower agreement. The
label of Normosol-R, for example, states: “The
solution is not intended to supplant transfusion of
whole blood or packed red cells in the presence
of uncontrolled hemorrhage”. What is the rela-
tion between Normosol-R and hemorrhage? In
this case, any of NOT ESTABLISHED, NOT REC-
OMMENDED, and OTHER seems acceptable.
We observe a correlation between the number
of distinct disease mentions in a drug label and
its ratio of TREATS labels against the other labels.
Some drugs are more “general purpose” than oth-
ers, in that they are involved in many treatment re-
lations. For example, the label for Prednisone con-
tains mentions of 50 distinct diseases it can treat.
To prevent our system from predicting treatment
relations primarily using the out-degree of drug
nodes (instead of the domain knowledge provided
by the graph), we manually removed 19 of these
high-degree drugs. After removing these drugs,
our dataset contained 431 relations.
2.3 Structured Medical Ontologies
Our graph contains structured information about
drugs and diseases from a variety of sources. Our
observations for drugs are route (OpenFDA),3
pharmacologic class (OpenFDA), substances
(OpenFDA), and dosage form (RxNorm).4
Our observations for diseases are all from
SNOMED CT:5 finding sites, associated mor-
phologies, and courses.
In general, these ontologies are quite sparse;
a missing edge is therefore not necessarily evi-
dence for a missing relationship. Broadly speak-
ing, this is why text analysis can be so meaning-
ful in this context – structured resources always
fall behind because of the challenges of manual
creation. This sparsity also motivates the approxi-
mate, text-based graph we introduce next.
3 Clinical Narratives Knowledge Graph
The Medical Ontologies Knowledge Graph is pre-
cise, but the underlying resources are expensive to
3https://open.fda.gov
4https://www.nlm.nih.gov/research/
umls/rxnorm/
5https://www.snomed.org
build, which creates sparsity and can be an obsta-
cle to adapting the ideas to new domains. To try
to address this, we built a comparable graph us-
ing only de-identified clinical narratives – reports
(often transcribed voice recordings) of clinicians’
interactions with patients.
Using lexicon-based matching methods, we ex-
tracted drug and disease mentions from these texts.
In the resulting graph, each text is a node, with
edges to the drug and disease nodes corresponding
to these extracted mentions. The resulting graph
has 319,598 nodes and 421,502 edges.
This is a simpler graph structure than we are
able to obtain from structured resources (cf. sec-
tion 2.3), but it supports our most important log-
ical connections. For example, we can say that
if diseases d1 and d2 are mentioned in the same
narrative and d1 is treated by a specific drug, then
d2 might also be treated by that drug. These hy-
potheses are often not supported; for example, a
patient with a number of unrelated medical con-
ditions might lead to many false instances of this
claim. Nonetheless, we expect that, in aggregate,
these connections will prove informative.
4 Models
Our core task is to identify drug–disease TREATS
relations based on the drug’s label text. We
consider text-only, graph-only, and combined ap-
proaches to this problem.
4.1 Text-Only Model
Our text-only model is a separately optimized con-
ditional random fields (CRF; Lafferty et al. 2001)
model trained on 2,000 annotated sentences sam-
pled from the full dataset of FDA drug labels.
When this CRF is used in isolation, we say that
a drug ci treats a disease dj just in case our trained
CRF identifies at least one TREATS span describ-
ing dj in the label for ci. To incorporate this CRF
into our PSL models, we simply add two logical
statements: one to influence the prediction confi-
dence positively, another negatively (table 2, rules
1a,b). This encodes the goal of agreeing with this
model’s predictions.
4.2 PSL Graph Rules
Our PSL rules fall into a few major classes. The
guiding intuitions are that (i) relations connecting
the same drug–disease pairs should have the same
confidence, (ii) drugs that have nodes in common
Priors
¬treats(ci, dj)
¬treats(ci, dj)
1a. ¬CRF treats(ci, dj) ⇒ ¬treats(ci, dj)
b. ¬CRF treats(ci, dj) ⇒ ¬treats(ci, dj)
2a. R(d1, x) ∧ R(d2, x) ∧ d1 6= d2 ∧ ¬treats(ci, d1) ⇒ ¬treats(ci, d2)
b. R(d1, x) ∧ R(d2, x) ∧ d1 6= d2 ∧ ¬treats(ci, d1) ⇒ ¬treats(ci, d2)
3a. S(c1, x) ∧ S(c2, x) ∧ c1 6= c2 ∧ ¬treats(c1, dj) ⇒ ¬treats(c2, dj)
b. S(c1, x) ∧ S(c2, x) ∧ c1 6= c2 ∧ ¬treats(c1, dj) ⇒ ¬treats(c2, dj)
Table 2: PSL rules. The diagrams show inferred edges (black) based on observed nodes and edges (gray), drug
nodes (green), and disease nodes (red). Variables ci and dj range over drugs and diseases, respectively. The first
two rules serve as priors on the TREATS relation. The relation R can be has associated morphology, has course,
or has finding site. The relation S can be has route, has substance, has doseform, or has pharmclass. The
variable x in turn ranges over the semantically appropriate entities given the relation in question. For the Clinical
Narratives Graph, both R and S have only the value is mentioned in and x ranges over clinical narratives.
should treat the same diseases, and (iii) diseases
that have nodes in common should be treated by
the same drugs. Table 2 schematizes the full set of
rules that we define over both our graphs.
4.3 Optimization
We use the Probabilistic Soft Logic package.6 De-
tails about our optimization choices are given in
appendix A.2. The rules for our full model (all in-
stances of the schemas in table 2), along with their
learned weights and groundings (supporting graph
configurations), are given in appendix A.3.
5 Experiments
Figure 2 reports our main results (see ap-
pendix A.1 for additional experimental details).
Both the CRF and the graph rules make positive
contributions, and any combination of these two
sources of information is superior to its text-only
or graph-only ablations. Furthermore, our Clin-
ical Narratives Graph proves extremely powerful
despite its simplistic construction. Numerically,
our best model for essentially any amount of ev-
idence is one that includes rules that reason about
both graphs in addition to the CRF predictions,
though using the Narratives Graph alone is highly
competitive with this larger one. These findings
strongly support our core hypothesis that informa-
tion extraction from drug labels can benefit from
both text analysis and graph-derived information.
6http://psl.linqs.org
Figure 2: Area under the Precision-Recall curve (AUC)
as function of evidence ratio (proportion of drug-
disease edges that are observed). We favor AUC over
receiver–operator curve (ROC) because the dataset is
highly imbalanced – only 24.8% of relations are pos-
itive for the TREATS label. Results are averaged over
100 runs for each model.
6 Conclusion
We presented evidence that combining text analy-
sis with PSL rules defined over a knowledge graph
can improve predictions about drug–disease treat-
ment relations, and we showed that this can be
effective even where the graph is derived heuris-
tically from clinical texts, which means that the
techniques can be applied even in domains that
lack rich, broad coverage ontologies.
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A Supplemental Material
A.1 Experimental Details
For each run, we sample two distinct sets of dis-
eases. Then, with each set, we create a subgraph
by considering all the drugs adjacent to these dis-
eases, and the edges between these drugs and dis-
eases. The two subgraphs have distinct disease
nodes, distinct edges, and some drug nodes in
common. One of these subgraphs is used for train-
ing, the other one for evaluation. In each subgraph,
we sample 25% of the edges that are used for pre-
diction. Depending on the evidence ratio, some
of the remaining 75% of the edges are provided
as observations to the model. For evidence ra-
tio = 0.75 for example, 75% of the edges in each
subgraph are observed and the other 25% are pre-
dicted by models.
A.2 Optimization details
In training, initial weight values are very impor-
tant. Whatever the learning rate and number of
steps, it is easy to get stuck in local optima. We
computed the initial weights using the number of
groundings for each rule, such that (i) each source
of information (CRF, ontologies, narratives) has
the same contribution, and (ii) for a given source
of information, each rule has the same contribu-
tion.
The weights were learned by optimizing the
pseudo-log-likelihood of the data using the voted
perceptron algorithm, as implemented by the PSL
package. We preferred the pseudo-log-likelihood
to the log-likelihood for scalability reasons.
Each model was trained over 10 iterations, with
a training step of 1.
For inference, we used the Alternating Di-
rection Method of Multipliers (ADMM; Boyd
et al. 2011), as implemented by the PSL pack-
age. Consensus and local variables were initial-
ized to a fixed value (0.25, close to the true pos-
itive TREATS edge ratio), instead of randomly, to
speed up convergence. The absolute and relative
error components of stopping criteria were set to
10−6, with a maximum of 25,000 iterations.
A.3 Learned weights and groundings
Rule Relative learned weight Groundings
Prior (positive) 1.10 431
Prior (negative) 0.87 431
Rule 1a 1.02 107
Rule 1b 0.98 324
Rule 2a with R = has associated morphology 1.05 3
Rule 2b with R = has associated morphology 1.11 30
Rule 2a with R = has course − 0
Rule 2b with R = has course 0.97 14
Rule 2a with R = has finding site 1.13 37
Rule 2b with R = has finding site 0.88 45
Rule 3a with S = has route 3.09 347
Rule 3b with S = has route 0.00 1,095
Rule 3a with S = has substance 1.36 65
Rule 3b with S = has substance 1.00 140
Rule 3a with S = has doseform 1.99 164
Rule 3b with S = has doseform 0.77 384
Rule 3a with S = has pharmclass 1.00 52
Rule 3b with S = has pharmclass 1.00 101
Rule 2a with R = is mentioned in 22.12 29,803
Rule 2b with R = is mentioned in 0.0 115,251
Rule 3a with S = is mentioned in 7.42 2,568
Rule 3b with S = is mentioned in 0.90 14,062
Table A1: Learned weights and groundings in our full model (evidence ratio = 0.75). Rule numbers refer to the
schemas in table 2. Weights are relative to their initial value (ratio of the learned weight over its respective initial
weight). Weights assigned to “positive” rules are often larger than the weight of their respective negative rule,
which suggests that positive groundings are usually more informative than negative ones. For example, drugs
that have the same route are more likely to have the same positive TREATS edges than to have the same negative
TREATS edges.
